You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

The Madrid Magnitude: Exploring Updates in Molecularly Altered Non-Small Cell Lung Cancer (NSCLC)

  • Authors: Pasi A. Jänne, MD, PhD; Marina Chiara Garassino, MD; Alexander Spira, MD, PhD, FACP
  • CME / ABIM MOC Released: 11/7/2023
  • Valid for credit through: 11/7/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.75 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, pathologists, pulmonologists, surgeons, and other members of the interdisciplinary care team who treat patients with non-small cell lung cancer (NSCLC).

The goal of this activity is to improve learners’ understanding of the recent data evaluating treatment strategies for patients with molecularly altered NSCLC and of how best to integrate these data into the clinical care of affected patients.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Evolving clinical trial data evaluating treatment strategies for patients with molecularly altered NSCLC
  • Have greater competence related to
    • Identifying patients with NSCLC who have targetable molecular alterations
  • Demonstrate greater confidence in their ability to
    • Integrate evolving evidence into the clinical care of patients with molecularly altered NSCLC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Pasi A. Jänne, MD, PhD

    Professor of Medicine
    Harvard Medical School
    Director, Lowe Center for Thoracic Oncology
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Disclosures

    Pasi A. Jänne, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc.; Accutar Biotech; Allorion Therapeutics; AstraZeneca; Bayer HealthCare; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Chugai Pharmaceuticals; Daiichi Sankyo; Eisai Inc.; Frontier Medicines; Hongyun Biotechnology; Lilly; Merus; Mirati Therapeutics; Monte Rosa; Novartis Pharmaceuticals; Nuvalent; Pfizer Inc.; Roche/Genentech, Inc.; Sanofi; Scorpion Therapeutics; SFJ Pharmaceuticals; Silicon Therapeutics; Syndax; Takeda Oncology; Transcenta; Voronoi
    Research funding from: Astellas Pharmaceuticals; AstraZenenca; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo; Lilly; Puma Biotechnology; Revolution Medicines; Takeda Oncology
    Royalties from: LabCorp; This is for post-marketing royalties from Dana Farber Cancer Institute owned intellectual property (I am an inventor on the patent) on EGFR mutations licensed to Lab Corp.

  • Marina Chiara Garassino, MD

    Professor of Medicine
    Hematology and Oncology
    Department of Medicine
    University of Chicago
    Chicago, Illinois

    Disclosures

    Marina Chiara Garassino, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc.; AstraZeneca; Abion; Bayer; Blueprint Medicines; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo; Italia S.p.A; Incyte Corporation; Janssen Pharmaceuticals; Lilly; OncoHost; Merck & Co., Inc.; Mirati; MSD International GmbH; Novartis Pharmaceuticals; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi; Seattle Genetics, Inc.; Takeda Pharmaceuticals North America, Inc.
    Research funding from: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Foundation Medicine; GlaxoSmithKline; Ignyta; Incyte Corporation; Italia S.p.A; Lilly; MedImmune Inc.; Merck & Co.; Merck & Co. International GmbH; Novartis Pharmaceuticals; Pfizer (MISP); Roche; Spectrum Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.; Tiziana Life Sciences

  • Alexander Spira, MD, PhD, FACP

    Medical Oncologist
    Co-Director, Virginia Cancer Specialists Research Institute
    Clinical Director, NEXT Oncology
    Fairfax, Virginia

    Disclosures

    Alexander Spira, MD, PhD, FACP, has the following relevant financial relationships:
    Consultant or advisor for: Amgen Inc.; Array BioPharma; AstraZeneca/MedImmune Inc.; Black Diamond Therapeutics; Blueprint Medicines; Daiichi Sankyo/AstraZeneca; Bristol Myers Squibb Company; Gritstone bio; Gritstone Oncology; Incyte Corporation; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Mersana Therapeutics; Mirati Therapeutics; Novartis Pharmaceuticals; Regeneron Pharmaceuticals, Inc.; Sanofi; Takeda Pharmaceuticals North America, Inc.
    Speaker or member of speakers bureau for: Amgen Inc.; AstraZeneca/MedIummune; Bayer HealthCare; Bristol Myers Squibb Company; CytomX Therapeutics; Janssen Oncology; Merck & Co., Inc.; Novartis Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.
    Research funding from: AbbVie Inc.; ADC Therapeutics; Alkermes, Inc.; Amgen Inc.; Arch Therapeutics; ArriVent Biopharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; BluPrint Oncology; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; CytomX Therapeutics; Daiichi Sankyo; Gritstone; Ignyta; Incyte Corporation; Janssen Oncology; LAM Therapeutics; Loxo; Macrogenics; Mersana Therapeutics; Medikine; MedImmune Inc.; Mirati Therapeutics; Nalo Therapeutics; Novartis Pharmaceuticals; Plexxikon; Regeneron Pharmaceuticals, Inc.; Revolution Medicines; Roche; Rubius Therapeutics; Scorpion Therapeutics; Synthekine; Takeda Pharmaceuticals North America, Inc.
    Stock options from: Lilly
    Owns stock (publicly traded) in: Lilly

Editor

  • Amy Furedy, RN, OCN

    Medical Education Director, Medscape, LLC

    Disclosures

    Amy Furedy, RN, OCN, has no relevant financial relationships.

Compliance Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

The Madrid Magnitude: Exploring Updates in Molecularly Altered Non-Small Cell Lung Cancer (NSCLC)

Authors: Pasi A. Jänne, MD, PhD; Marina Chiara Garassino, MD; Alexander Spira, MD, PhD, FACPFaculty and Disclosures

CME / ABIM MOC Released: 11/7/2023

Valid for credit through: 11/7/2024, 11:59 PM EST

processing....

Contents of This Activity

To start this activity, please assess your clinical knowledge by completing the brief survey at the bottom. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Molecularly Altered NSCLC: From Diagnostics to Therapy

Do you know how to best determine treatment for your patients with molecularly altered NSCLC?
Pasi A. Jänne, MD, PhD

Clinical Updates and Implications for EGFR- and ALK-Positive NSCLC

Get the latest information on EGFR- and ALK-positive NSCLC.
Pasi A. Jänne, MD, PhD; Alexander Spira, MD, PhD, FACP

Updates and Implications for Therapies Targeting KRAS, ROS1, BRAF, and Other Alterations in NSCLC

Learn the most up-to-date management strategies for your patients with molecularly altered NSCLC.
Pasi A. Jänne, MD, PhD; Marina Chiara Garassino, MD
 

Learning Feedback Questions

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

  • Print